Amgen launches second trial for Alzheimer’s product
Amgen and Novartis launched a second trial for a product intended to delay or prevent Alzheimer’s disease, in partnership with the Banner Alzheimer’s Institute. The biotech giant based in Thousand Oaks had previously collaborated on the first study in the Alzhiemer’s Prevention Initiative Generation program, which enrolled participants who had two copies of the apolipoprotein Read More →
Amgen buying out joint venture Kirin-Amgen for $780 million
Amgen, the biotech giant based in Thousand Oaks, announced that it would buy out joint venture Kirin-Amgen, which was created to develop white blood cell booster Neupogen among other projects, for $780 million. The joint venture holds intellectual property rights for Neupogen, Neulasta, Aranesp, Nplate and brodalumab. In addition to the cash deal, Amgen will Read More →
Amgen product sales slip but income stays steady
Net income at biotech giant Amgen stayed flat for the third quarter, despite a slight downtick in revenues to $5.8 billion, the company reported Oct. 25. Product sales saw a slight decline, including Neupogen, Epogen and its blockbuster rheumatoid arthritis drug Enbrel, which fell 6 percent, but net income stayed steady at a little more Read More →
Biotech giant Amgen to pay dividend on Dec. 8
Biotech giant Amgen announced Oct. 24 that it would pay a $1.15 dividend for its fourth quarter of fiscal 2017. Stockholders of record for the Thousand Oaks-based company at the end of day on Nov. 17 will receive the dividend on Dec. 8.
Westlake Village biotech company MannKind restructures debt
MannKind announced Oct. 23 that it had restructured debt due in 2018, exchanging $27.7 million in convertible notes for $23.7 million due in October of 2021 and nearly 1 million shares of its common stock. The new convertible senior subordinated exchange notes have a rate of 5.75 percent, the Westlake Village-based biotech company said in Read More →
Amgen studying genes to target pain conditions
For the next year, Amgen and Boston Children’s Hospital will use genetic analysis to study pain sensitivity. The biotech giant based in Thousand Oaks will work with patients who have abnormal pain conditions, and the hospital will validate genetic markers as potential targets for new therapies, the two announced in a press release on Oct. 16. “Traditional Read More →
Amgen settles with AbbVie over Humira biosimilar litigation
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
